Arvinas and Pfizer out-license VEPPANU to Rigel for $85M upfront; potential $320M milestones

ARVINAS, INC.

Rigel pays $70M upfront plus up to $15M upon completion of transition activities; split evenly with Pfizer.
Arvinas and Pfizer eligible for up to $320M in development, regulatory, and commercial milestones.
Tiered royalties on worldwide net sales in the mid-teens to mid-20s, also split evenly.
Rigel contributes up to $40M toward ongoing development; Arvinas/Pfizer continue current activities.
Closing subject to HSR waiting period; NCCN added vepdegestrant as Category 2A on May 8, 2026.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

ARVINAS, INC. entered into License Agreement with Rigel Pharmaceuticals, Inc. valued at $70.0 million (effective 2026-05-11).

Action: entry
Agreement: license
Counterparty: Rigel Pharmaceuticals, Inc.
Value: $70.0 million
Effective: 2026-05-11

Exact text from the filing

On May 11, 2026, Arvinas, Inc., a Delaware corporation (“Arvinas”), and Arvinas’ direct subsidiaries, Arvinas Operations, Inc. (“Operations”) and Arvinas Estrogen Receptor, Inc. (“Arvinas ER,” together with Arvinas and Operations, the “Company”), together with Pfizer Inc. (“Pfizer”), entered into a license agreement (the “License Agreement”) with Rigel Pharmaceuticals, Inc. (“Rigel”).

View on SEC.gov

622 material agreements filed in the last 30 days. Browse all material agreements →

ARVINAS, INC. filing history →

Source: SEC EDGAR

accession 0001628280-26-033874

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.